{"filings":[{"id":815836,"accession_number":"0001193125-26-254615","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-06-03T11:58:30+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NewAmsterdam Pharma shareholders approve 2026 ESPP, re-elect directors at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2026 Employee Stock Purchase Plan; up to 1,150,000 ordinary shares available, 15% discount on lower of start/end market price.","Purchase periods generally 6 months; payroll deductions 1%-15% of compensation; plan expires June 2, 2036.","Re-appointed John W. Smither and Janneke van der Kamp as non-executive directors until 2030 AGM.","Board authorized to issue shares (including without pre-emption rights) through June 2, 2031.","Say-on-pay passed with 81.1M for; Deloitte ratified as auditor for FY2026; quorum 78.3%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96809,"accession_number":"0001193125-26-210283","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.","Cash and marketable securities $707.3M at March 31, down from $728.9M at Dec 31, 2025.","Regulatory decisions on obicetrapib from EMA, UK, Switzerland expected in 2H26; potential launches by Menarini in 4Q26 in Germany and UK.","PREVAIL CVOT interim analysis planned for 4Q2026, result expected 1Q2027; trial may stop for efficacy or complete by end of 2027.","Completed enrollment in REMBRANDT Phase 3 (323 patients); RUBENS Phase 3 topline data expected by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":3040000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96808,"accession_number":"0001193125-26-177406","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NewAmsterdam Pharma CAO Louise Kooij to depart Aug 31, 2026; severance terms set","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Louise Kooij to step down as Chief Accounting Officer effective August 31, 2026.","Separation agreement includes 12 months base salary lump sum and pro-rated 2026 bonus.","Vesting of outstanding stock options and RSUs extended to Jan 10, 2027; exercise period to Feb 10, 2027.","Agreement includes confidentiality, non-compete, non-disparagement covenants and claims release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111057,"accession_number":"0001193125-26-084266","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma files updated corporate presentation, no specific details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated investor presentation on its website on March 2, 2026.","Presentation furnished as Exhibit 99.1 to this Form 8-K but not reproduced in available text.","No financial or operational updates explicitly provided in the filing text.","Content of the presentation is unknown; cannot extract specific numbers or events.","Confidence low due to lack of exhibit content and absence of material disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111056,"accession_number":"0001193125-26-056020","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.","Cash position $728.9M at Dec 31, 2025; net loss $203.8M for FY2025.","Topline data from RUBENS Phase 3 trial (type 2 diabetes/metabolic syndrome) expected by year-end 2026.","PREVAIL CVOT blinded event rate through initial 12 months tracking in line with BROADWAY.","Plan to initiate Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111055,"accession_number":"0001193125-26-008300","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.","EMA approval decision for obicetrapib monotherapy and FDC expected in 2H26.","PREVAIL CVOT overall MACE event rate tracking in line with BROADWAY; fully enrolled with >9,500 patients.","First patient enrolled in RUBENS Phase 3 trial for metabolic syndrome; topline data expected year-end 2026.","Plans to initiate first dedicated Alzheimer's trial in 2026 based on positive biomarker data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127681,"accession_number":"0001193125-25-265800","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.","Net loss $72.0M in Q3 2025 vs $16.6M loss in Q3 2024; revenue fell to $0.3M from $29.1M.","European Medicines Agency accepted MAAs for obicetrapib monotherapy and FDC with ezetimibe.","R&D expenses $31.0M (down 13% YoY); SG&A $24.5M (up 33% YoY), driven by personnel and share-based compensation.","Ongoing Phase 3 trials: PREVAIL CVOT (>9,500 enrolled), REMBRANDT plaque imaging, and RUBENS (diabetes) expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":22471000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144458,"accession_number":"0000950170-25-112345","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma posts updated corporate investor presentation on Sep 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on company website and furnished as an exhibit to the Form 8-K.","Filing provides no specific financial results, pipeline updates, or material changes.","Content of the presentation was not reproduced in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144457,"accession_number":"0000950170-25-109567","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EMA validates MAA for NewAmsterdam's obicetrapib monotherapy and FDC with ezetimibe","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA will review Phase 3 BROADWAY, BROOKLYN and TANDEM trials supporting obicetrapib 10 mg and obicetrapib/ezetimibe FDC.","NewAmsterdam eligible for up to €863M in milestones and tiered double-digit to mid-twenties % royalties on Menarini territory net sales.","Obicetrapib monotherapy showed 33-36% LDL-C reduction vs placebo; FDC showed ~50% reduction in TANDEM trial.","MAA submitted by partner Menarini under exclusive license agreement signed June 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144456,"accession_number":"0000950170-25-109387","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"NewAmsterdam enters supply agreement with Menarini for obicetrapib products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.","Subsidiary will be exclusive supplier initially; price based on cost of goods sold plus a specified mark-up.","Parties to initiate manufacturing transfer to Menarini; subsidiary grants non-exclusive license for manufacturing.","Supply term runs with License Agreement (from June 2022); subsidiary can terminate on 120 days’ notice after transfer or 2 years.","Either party may terminate for uncured material breach, insolvency, or force majeure exceeding 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144455,"accession_number":"0000950170-25-103520","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.","Revenue $19.1M (vs $2.3M YoY) driven by $16.1M Menarini development milestone.","R&D expenses $27.5M (vs $38.4M YoY) on lower clinical costs; SG&A $27.3M (vs $16.5M YoY) on pre-commercial investment.","Net loss $17.4M compared to $39.0M in Q2 2024; improvement from higher revenue and lower R&D.","EMA marketing authorisation application on track for 2H25; BROADWAY AD biomarker data showed significant p-tau217 reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":22123000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144454,"accession_number":"0000950170-25-099891","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).","ApoE4/E4 carriers showed 20.48% mean p-tau217 reduction vs placebo (p=0.010).","Favorable trends observed in NFL, GFAP, p-tau181, and Aβ42/40 biomarkers.","Safety in BROADWAY overall was comparable to placebo; AD analysis not independently evaluated.","Company plans to discuss results with regulators and explore next steps for AD program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144453,"accession_number":"0001193125-25-158211","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amended agreement effective July 1, 2025; replaces November 2022 pact.","Termination without cause entitles Kastelein to 12 months base salary, earned bonus, and prorated annual bonus.","Change-in-control trigger: same severance plus acceleration of all time-based stock options and equity awards.","Exercise period for certain vested options extended upon qualifying termination.","Kastelein remains Chief Scientific Officer and a director; no departure announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162825,"accession_number":"0000950170-25-084663","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma holds R&D Day; no material updates extracted from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company hosted R&D Day on June 11, 2025 in New York City with live webcast.","Presentation furnished as Exhibit 99.1, but no specific pipeline or financial data disclosed in available text.","No concrete numeric updates on obicetrapib trials, revenue, or guidance provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162824,"accession_number":"0001193125-25-137432","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam reports positive AD biomarker data from BROADWAY; p-tau217 reduced in ITT and ApoE4 carriers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).","AD sub-study included 1,727 patients, 367 ApoE4 carriers; primary measure was p-tau217 change.","Company plans to present full results at AAIC conference in Toronto in July 2025.","Results build on prior genetic, preclinical, and Phase 2a data supporting CETP inhibition for AD prevention.","Obicetrapib is an oral CETP inhibitor primarily developed for LDL-C reduction; safety shown in large trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162823,"accession_number":"0001193125-25-137119","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"All nine proposals approved at NewAmsterdam Pharma 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.","Dutch statutory annual accounts for FY2024 approved: 83.5M for, 5.6K against.","Three non-executive directors (Joustra, McKenna, Gulfo) each elected with >79M for votes.","Michael Davidson reappointed executive director (70.5M for, 9.2M against); James Topper reappointed non-executive.","Share buyback authorization extended (71.4M for, 12.2M against); say-on-pay approved and set for annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162822,"accession_number":"0000950170-25-066410","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.","Net loss $39.5M vs $93.8M YoY; revenue $3.0M vs $1.4M.","EMA submission expected 2H25 by partner Menarini; PREVAIL CVOT enrollment completed.","Adele Gulfo appointed to Board of Directors in April 2025.","R&D expenses $44.8M; SG&A $27.2M, up due to commercial launch prep."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":2978000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162821,"accession_number":"0001193125-25-114456","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).","TANDEM trial fixed-dose combination of obicetrapib and ezetimibe achieved 48.6% LDL-C reduction vs placebo (p<0.001).","Pooled Lp(a) analysis across three Phase 3 trials showed a median placebo-adjusted reduction of 45% at 12 weeks.","Obicetrapib plus moderate statins lowered LDL-C by 69% (atorvastatin 20 mg) and 64% (rosuvastatin 10 mg) in a Phase 2 trial.","Phase 2 data showed synergy in plaque prevention: combination of obicetrapib and ezetimibe reduced plaque formation by 98% vs 78% independently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162820,"accession_number":"0001193125-25-084428","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma appoints Adele Gulfo as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.","Granted options for 50,700 ordinary shares at $16.06/share, vesting over 3 years with 33% on first anniversary.","Granted 10,860 RSUs vesting in equal thirds over three years from April 15, 2025.","Gulfo led launches of Lipitor and Crestor; oversaw $12B+ revenue at Pfizer's U.S. primary care unit.","Appointment adds commercial expertise as company prepares for potential obicetrapib launch in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180781,"accession_number":"0000950170-25-027336","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.","Revenue of $45.6M (FY2023: $14.1M) driven by a clinical milestone and cost reimbursement.","Net loss widened to $241.6M from $176.9M; R&D spend fell to $151.4M while SG&A rose to $70.4M.","Phase 3 BROADWAY met primary endpoint with 33% LDL-C reduction; TANDEM FDC achieved 49% reduction; BROOKLYN showed 36% reduction.","EMA submission planned for 2H25 via partner Menarini; USPTO issued obicetrapib solid-form patent until July 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":45563000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180780,"accession_number":"0001193125-25-004142","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.","Unaudited year-end cash of $835 million; funds operations through PREVAIL CVOT readout and potential commercial launch.","Menarini to submit EMA filing for obicetrapib in 2H2025; additional Phase 3 data presentations planned throughout 2025.","VINCENT Phase 2 trial exploring obicetrapib +/- PCSK9i on Lp(a) expected to complete in 2H2025.","USPTO issued composition-of-matter patent for obicetrapib, providing IP protection in US until July 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197628,"accession_number":"0001193125-24-277937","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.","Offering upsized from initial $300M to $416.5M; underwriters exercised option to buy additional 2,550,000 shares.","Net proceeds to company expected ~$452.6M after underwriting discounts and estimated offering expenses.","Closing expected on or about December 13, 2024, subject to customary conditions.","Joint book-running managers: Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities, William Blair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197627,"accession_number":"0001193125-24-274327","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NewAmsterdam Pharma terminates $150M ATM equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.","Program allowed for sale of up to $150M of ordinary shares.","No sales will be made under Sales Agreement until new prospectus or registration statement is filed.","Sales Agreement remains in full force and effect other than the terminated ATM prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197626,"accession_number":"0001193125-24-273959","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.","Observed 21% reduction in MACE (exploratory endpoint) at one year; hazard ratio 0.79 (95% CI 0.54-1.15).","Obicetrapib well-tolerated: TEAEs 59.8% vs placebo 60.9%; discontinuation 11.1% vs 12.4%.","NewAmsterdam plans to present additional BROADWAY data at upcoming medical meetings and discuss filings with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197625,"accession_number":"0001193125-24-262125","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma reports positive Phase 3 TANDEM topline data; FDC lowers LDL-C 48.6% vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg achieved LS mean LDL-C reduction of 48.6% (p<0.0001) vs placebo at day 84.","All co-primary endpoints met with statistical significance; FDC superior to both monotherapies (p<0.001).","Over 60% of FDC patients saw >50% LDL-C reduction; ~71% achieved LDL-C <55 mg/dL.","Safety well-tolerated; drug-related TEAEs 2.9% in FDC arm vs 3.9% placebo; no serious TEAEs.","Data supports global regulatory filings for the FDC tablet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197624,"accession_number":"0001193125-24-260923","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.","Lp(a) mean reduction vs placebo 45.9% at day 84; total LDL particles reduced 52.5% at day 180.","Safety comparable to placebo; discontinuation rate 7.6% for obicetrapib vs 14.4% for placebo.","Trial enrolled 354 HeFH patients; mean baseline LDL-C 123 mg/dL despite high statin use (79%) and ezetimibe (54%).","Data presented at AHA 2024; topline from TANDEM and BROADWAY studies expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197623,"accession_number":"0000950170-24-121827","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.","Revenue $29.1M in Q3 2024 from Menarini milestone; net loss $16.6M vs $47.1M in Q3 2023.","Phase 3 TANDEM topline data now expected in Q4 2024 due to faster enrollment.","On track for BROADWAY topline data in Q4 2024; BROOKLYN data at AHA Nov 16-18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197622,"accession_number":"0001193125-24-239687","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.","Errors: weighted average ordinary shares outstanding incorrectly used ending shares instead of weighted average.","Restatement affects only IFRS-based financials in 2022 Annual Report; 2023 US GAAP financials not impacted.","Company intends to file amendment to 2022 Annual Report as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213858,"accession_number":"0001193125-24-197971","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma enters $150M ATM equity offering with TD Cowen as agent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Sales Agreement replaces Cowen and Company with TD Cowen as sole sales agent.","Company may issue and sell up to $150M in ordinary shares at market prices via ATM offering.","No shares were sold under the prior December 2023 sales agreement.","TD Cowen receives up to 3% commission on gross sales; company has no obligation to sell.","Sales may be made through an affiliate of TD Cowen; agreement terminable at will by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213857,"accession_number":"0000950170-24-092279","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.","US composition of matter patent issued for obicetrapib, extending IP protection to July 2043.","Cash $430.7M as of June 30, 2024 (up from $340.5M at Dec 31, 2023).","Q2 net loss $39.0M ($0.41 diluted EPS) vs $38.3M ($0.47) year ago; revenue $2.3M (vs $1.7M).","Topline data for Phase 3 BROADWAY expected Q4 2024; Phase 3 TANDEM enrollment completed, topline Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":3680000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213856,"accession_number":"0001193125-24-186747","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.","51% of patients on obicetrapib achieved LDL-C below 70 mg/dL.","Safety comparable to placebo; TEAEs 63.7% vs 70.3%, discontinuation 7.6% vs 14.4%.","Mean baseline LDL-C was 123 mg/dL despite 79% on high-intensity statins.","Next data readouts: BROADWAY (Q4 2024) and TANDEM (Q1 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213855,"accession_number":"0001193125-24-180754","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.","Wouter Joustra (Forbion general partner) and Mark C. McKenna (Mirador CEO) appointed as temporary non-executive directors.","McKenna granted options for 72,500 ordinary shares at $18.81 per share, vesting over 3 years.","McKenna also joins audit and compensation committees; Joustra brings capital markets and venture experience.","Appointments effective immediately; formal ratification expected at next annual general meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233078,"accession_number":"0001193125-24-158751","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.","Patent protection extends to July 2043, over 9 years beyond prior second-generation patent expiration in 2034.","Nine total patents now issued or allowed by USPTO covering obicetrapib and its uses.","Patent eligible for listing in FDA Orange Book as drug substance patent if product approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233077,"accession_number":"0001193125-24-157374","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma shareholders approve all proposals at 2024 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 57.6M shares (64% of eligible) voted; all seven proposals passed.","Proposal 6 (reappointment of Louis Lange): 34.5M For, 13.2M Against, 357k Abstain.","Proposal 5 (appointment of William H. Lewis): 48.1M For, 10.7k Against, 1.2k Abstain.","Adopted 2023 annual accounts, discharged directors, ratified Deloitte as auditor for 2024.","Item 8.01 refiled a license agreement with Menarini omitted from 2023 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233076,"accession_number":"0000950170-24-056292","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.","Cash position $481.1M at March 31, vs $340.5M Dec 31, bolstered by $190M public offering.","Net loss $93.8M ($1.06/diluted share) vs $42.0M ($0.51) year ago; revenue fell to $1.4M from $8.6M.","Dosed first patients in TANDEM (fixed-dose obicetrapib/ezetimibe); topline expected Q1 2025.","Appointed William H. Lewis as Board Chair and Juliette Audet as Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1401000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233075,"accession_number":"0001193125-24-082723","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma appoints Juliette Audet as CBO, effective April 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Juliette Audet appointed Chief Business Officer, effective April 1, 2024.","Audet resigns from Board of Directors; no disagreement with company.","Audet was a Partner at Forbion and previously on the Board since 2020.","Company expects two pivotal readouts for obicetrapib in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251227,"accession_number":"0001193125-24-056922","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NewAmsterdam Pharma posts updated investor presentation; no material new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate investor presentation on its website on March 4, 2024.","Presentation contains no new financial results, guidance, or material operational updates.","No earnings, M&A, or clinical data disclosed in the filing or exhibit.","Routine update typical for investor relations purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251226,"accession_number":"0001193125-24-049263","cik":1936258,"company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.","Cash at Dec 31, 2023: $340.5M; proforma cash after Feb 2024 $202M upsized offering ~$500M.","Phase 3 BROOKLYN topline in HeFH expected 3Q2024; BROADWAY in ASCVD expected 4Q2024.","PREVAIL CVOT enrollment to complete 1Q2024; topline data expected 2026. TANDEM FDC trial initiation 1Q2024 with data 1Q2025.","Appointed William H. Lewis as Board Chair; Phase 2 data showed significant LDL-C lowering with placebo-like safety."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":14090000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4274009451.2921634,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}